Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217868 | 1.00 | ABCB1 (0.40) | ABCB1POLLSMN1; SMN2ROCK2LMNA | |
| SCHEMBL9177307 | 0.98 | POLL (0.39) | ABCB1POLLSMN1; SMN2ROCK2NR3C1 | |
| SCHEMBL5674190 | 0.95 | POLL (0.39) | ABCB1POLLLMNAMEN1KMT2A | |
| SCHEMBL8960493 | 0.91 | ABCB1 (0.35) | ABCB1POLLSMN1; SMN2ROCK2LMNA | |
| SCHEMBL4444992 | 0.90 | SMN1; SMN2 (0.38) | ABCB1SMN1; SMN2LMNANPSR1MEN1 | |
| SCHEMBL3023273 | 0.90 | HPGD (0.40) | ABCB1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL29841836 | 0.90 | HPGD (0.40) | ABCB1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL8149220 | 0.89 | ROCK2 (0.36) | ABCB1POLLSMN1; SMN2ROCK2LMNA | |
| SCHEMBL28353796 | 0.88 | HPGD (0.40) | ABCB1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL28439942 | 0.88 | HTR7 (0.40) | ABCB1SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-21 | — | — | US | disclosed |
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9796678-B2 | Method for manufacturing optically active compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| EP-3153492-A1 | NOVEL COMPOUND AND FRAGRANCE COMPOSITION CONTAINING SAME | Takasago International Corporation (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20170088503-A1 | NOVEL COMPOUND, AND FLAVOR COMPOSITION AND/OR FRAGRANCE COMPOSITION CONTAINING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-03-30 | — | — | US | disclosed |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9284246-B2 | Method for producing optically active 2,3-dihydrofarnesal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-03-15 | — | — | US | disclosed |
| EP-2966054-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6342644-B1 | MULTISTAGE PROCESS OF HYDROGENATION WITH PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-29 | — | — | US | disclosed |
| US-20020007094-A1 | Method for producing 1-menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1153908-A2 | Method for producing 1-menthol | Takasago International Corporation (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-0570764-B1 | Asymmetric hydrogenation | HOFFMANN LA ROCHE (CH) | 2001-07-18 | — | — | EP | disclosed |
| US-5750690-A | HYDROGENATION OF A 1,2-DIALKYLOXO-3-CARBOXY-3-PYRAZOLINE OR 1,2,5,6-TETRAHYDROPYRIDAZINE OR DERIVATIVE; INTERMEDIATES FOR THE HYPOTENSIVE AGENT, ?CILAZAPRIL? | HOFFMANN-LA ROCHE INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0570764-A2 | Asymmetric hydrogenation | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | ABCB1 4330/4885POLL 547/4885SMN1; SMN2 3481/4885 |
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | FZD7, TAS1R1, TAS2R5 | ABCB1 4295/4885POLL 942/4885SMN1; SMN2 2390/4885 |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | ABCB1 4014/4885POLL 689/4885SMN1; SMN2 2938/4885 |
| US-20020007094-A1 | Method for producing 1-menthol | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PHOSPHO1 | ABCB1 4814/4885POLL 1138/4885SMN1; SMN2 4686/4885 |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | C9, C5, PRMT7 | ABCB1 3882/4885POLL 3695/4885SMN1; SMN2 3976/4885 |
| US-20170088503-A1 | NOVEL COMPOUND, AND FLAVOR COMPOSITION AND/OR FRAGRANCE COMPOSITION CONTAINING SAME | FZD7, TAS2R5, TAS2R40 | ABCB1 4543/4885POLL 1565/4885SMN1; SMN2 3007/4885 |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | FNTB, FNTA, LSS | ABCB1 3451/4885POLL 3245/4885SMN1; SMN2 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.